Article | August 29, 2022

Planning For Diversity

By Rachael Fones, Director, Government & Public Affairs and Strategic Advisor, Diversity in Clinical Trials at IQVIA


Efforts to make clinical trials more diverse received a potentially game-changing boost from the US Food and Drug Administration (FDA). In April 2022, the FDA released another guidance on diversity in clinical trials – this time with a clear focus on upfront planning and goal setting earlier in development.

The draft guidance, entitled Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials, expands on an existing but lesser-recognized 2016 recommendation that sponsors submit a Race and Ethnicity Diversity Plan for discussion before starting Phase III.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader

IQVIA Research & Development Solutions